Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Decreases By 8.7%

Aileron Therapeutics, Inc. (NASDAQ:ALRN) saw a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 233,300 shares, a drop of 8.7% from the October 15th total of 255,600 shares. Based on an average daily volume of 74,800 shares, the short-interest ratio is presently 3.1 days. Approximately 1.2% of the shares of the company are sold short.

Institutional Trading of Aileron Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ALRN. Texas Capital Bank Wealth Management Services Inc increased its stake in shares of Aileron Therapeutics by 65.9% during the first quarter. Texas Capital Bank Wealth Management Services Inc now owns 26,171 shares of the company’s stock valued at $174,000 after acquiring an additional 10,398 shares during the period. KG&L Capital Management LLC acquired a new position in shares of Aileron Therapeutics during the 3rd quarter valued at $46,000. Warberg Asset Management LLC bought a new stake in shares of Aileron Therapeutics in the 2nd quarter worth $86,000. Geode Capital Management LLC lifted its holdings in shares of Aileron Therapeutics by 34.8% in the third quarter. Geode Capital Management LLC now owns 229,817 shares of the company’s stock valued at $814,000 after buying an additional 59,370 shares during the period. Finally, Sigma Planning Corp boosted its stake in Aileron Therapeutics by 68.3% during the third quarter. Sigma Planning Corp now owns 212,410 shares of the company’s stock valued at $752,000 after buying an additional 86,185 shares in the last quarter. 90.89% of the stock is currently owned by institutional investors.

Aileron Therapeutics Stock Up 0.7 %

Shares of NASDAQ ALRN opened at $2.89 on Tuesday. The firm’s 50-day simple moving average is $3.49 and its 200 day simple moving average is $3.12. The stock has a market cap of $62.61 million, a P/E ratio of -0.93 and a beta of 2.35. Aileron Therapeutics has a fifty-two week low of $1.61 and a fifty-two week high of $7.42.

About Aileron Therapeutics

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).